Literature DB >> 10732806

A novel mutation in the predicted TM2 domain of the presenilin 2 gene in a Spanish patient with late-onset Alzheimer's disease.

J I Lao1, K Beyer, L Fernández-Novoa, R Cacabelos.   

Abstract

Mutations in the presenilin-2 (PS-2) gene are less frequent than mutations in the PS-1 gene. All mutations described in the PS-1 gene were found in early-onset Alzheimer's disease (AD) patients. At present, there are two missense mutations described for the PS-2 gene in some AD pedigrees. We have therefore analyzed transmembrane 2 (TM2) and TM5 domains of the PS-2 gene in AD patients and in a group of age-matched healthy controls. In a patient who was clinically diagnosed as having late-onset AD, we found a novel missense mutation consisting of a G->A substitution on exon 5 of the PS-2 gene, which results in a Val to Ile substitution at codon 148 within the predicted TM2 domain of the PS-2 protein. This is the third mutation described in the PS-2 gene and the first presenilin mutation detected in a Spanish AD patient. Both, the N141I mutation and the V148I mutation described here are located within the predicted TM2 domain and both were found in late-onset AD kindreds, whereas the mutation within the predicted TM5 domain was found in an early-onset AD pedigree. Carriers of mutations within TM2 of PS-1 have a mean age at onset of 40 years, while the other mutations in PS-1 occur in families with a mean age at onset of 47 years. In summary, we report here the first mutation in a presenilin gene in a Spanish AD case, which is the third mutation detected for the PS-2 gene.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10732806     DOI: 10.1007/s100480050044

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  7 in total

1.  Alzheimer's disease phenotypes and genotypes associated with mutations in presenilin 2.

Authors:  Suman Jayadev; James B Leverenz; Ellen Steinbart; Justin Stahl; William Klunk; Cheng-En Yu; Thomas D Bird
Journal:  Brain       Date:  2010-04       Impact factor: 13.501

Review 2.  Genetics, transcriptomics, and proteomics of Alzheimer's disease.

Authors:  Andreas Papassotiropoulos; Michael Fountoulakis; Travis Dunckley; Dietrich A Stephan; Eric M Reiman
Journal:  J Clin Psychiatry       Date:  2006-04       Impact factor: 4.384

Review 3.  Mutations in presenilin 2 and its implications in Alzheimer's disease and other dementia-associated disorders.

Authors:  Yan Cai; Seong Soo A An; SangYun Kim
Journal:  Clin Interv Aging       Date:  2015-07-14       Impact factor: 4.458

4.  Identification of PSEN1 and APP gene mutations in Korean patients with early-onset Alzheimer's disease.

Authors:  Hyun-Kyung Park; Duk Lyul Na; Jae-Hong Lee; Jong-Won Kim; Chang-Seok Ki
Journal:  J Korean Med Sci       Date:  2008-04       Impact factor: 2.153

Review 5.  The genetics of Alzheimer's disease.

Authors:  Eva Bagyinszky; Young Chul Youn; Seong Soo A An; SangYun Kim
Journal:  Clin Interv Aging       Date:  2014-04-01       Impact factor: 4.458

6.  Pleiotropic Effects of Variants in Dementia Genes in Parkinson Disease.

Authors:  Laura Ibanez; Umber Dube; Albert A Davis; Maria V Fernandez; John Budde; Breanna Cooper; Monica Diez-Fairen; Sara Ortega-Cubero; Pau Pastor; Joel S Perlmutter; Carlos Cruchaga; Bruno A Benitez
Journal:  Front Neurosci       Date:  2018-04-10       Impact factor: 4.677

Review 7.  Potential Therapeutic Approaches to Alzheimer's Disease By Bioinformatics, Cheminformatics And Predicted Adme-Tox Tools.

Authors:  Speranta Avram; Maria Mernea; Carmen Limban; Florin Borcan; Carmen Chifiriuc
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.